Patient Characteristics and Peripheral Blood Responses to GM-CSF (Congenital PAP)
| Patient No. . | Duration GM-CSF (d) . | Mean Daily Dose (d 1-21) (μg/kg) . | Baseline Cell Counts (×109/L) . | Peak Cell Counts Before Day 21 (×109/L) . | ||||
|---|---|---|---|---|---|---|---|---|
| Total WBC . | Neutrophils . | Eosinophils . | Total WBC . | Neutrophils . | Eosinophils . | |||
| 13 | 141 | 3.1 | 15.2 | 11.6 | 0.61 | 52.2 | 39.8 | 7.74 |
| 14 | 42 | 2.0 | 19.5 | 11.0 | 0.70 | 47.1 | 24.3 | 3.50 |
| 15* | 50 | 4.9 | 16.2 | 10.4 | 0.97 | 26.7 | 16.3 | 2.67 |
| 16 | 23 | 4.0 | 20.2 | 9.1 | 2.63 | 57.0 | 32.4 | 25.35 |
| 17* | 67 | 2.8 | 18.4 | 8.8 | 0.92 | 41.5 | 26.2 | 5.12 |
| Mean (SD) | 65 (46) | 3.4 (1.1) | 17.9 (2.1) | 10.2 (1.2) | 1.17 (0.83) | 44.9 (11.7) | 27.8 (8.9) | 8.88 (9.41) |
| Patient No. . | Duration GM-CSF (d) . | Mean Daily Dose (d 1-21) (μg/kg) . | Baseline Cell Counts (×109/L) . | Peak Cell Counts Before Day 21 (×109/L) . | ||||
|---|---|---|---|---|---|---|---|---|
| Total WBC . | Neutrophils . | Eosinophils . | Total WBC . | Neutrophils . | Eosinophils . | |||
| 13 | 141 | 3.1 | 15.2 | 11.6 | 0.61 | 52.2 | 39.8 | 7.74 |
| 14 | 42 | 2.0 | 19.5 | 11.0 | 0.70 | 47.1 | 24.3 | 3.50 |
| 15* | 50 | 4.9 | 16.2 | 10.4 | 0.97 | 26.7 | 16.3 | 2.67 |
| 16 | 23 | 4.0 | 20.2 | 9.1 | 2.63 | 57.0 | 32.4 | 25.35 |
| 17* | 67 | 2.8 | 18.4 | 8.8 | 0.92 | 41.5 | 26.2 | 5.12 |
| Mean (SD) | 65 (46) | 3.4 (1.1) | 17.9 (2.1) | 10.2 (1.2) | 1.17 (0.83) | 44.9 (11.7) | 27.8 (8.9) | 8.88 (9.41) |
*These patients were treated with yeast-derived recombinant GM-CSF (Leukine; Immunex); all other patients received bacterially synthesized recombinant GM-CSF (Leucomax; Schering-Plough).